Pharmaceutical Technology

JULY 1, 2025

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Sign up for our daily news round-up!

FDA 52

FDA Packaging Communication Hospitals 52

pharmaphorum

JULY 18, 2025

Find out more about the event here: [link] Image 18 July, 2025 Hanson Wade Bookmark this Oncology Taking chemotherapy directly to skin lesions, with Dr Raza B. Partner Content Partner Content Unlocking the Potential of Targeting the Innate Immune Syste. Ready to Catalyze the Next Wave of Inflammasome Therapies?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Compounding 52

pharmaphorum

AUGUST 18, 2022

Checkpoint inhibitors are a growing class of immunotherapy drugs that use monoclonal antibodies to activate checkpoint proteins, thus helping reactivate parts of the patient’s immune system that a cancer cell has shut down. The post Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings appeared first on.

Chemotherapy 52

Chemotherapy Immunization 52

pharmaphorum

JUNE 8, 2021

“If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. million in 2030.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 105